New biological therapies in Sjögren's syndrome

Best Practice and Research: Clinical Rheumatology

Volumn 29, Issue 6, 2015, Pages 783-793

  Nocturne, Gaetane ^a,b,e   Cornec, Divi ^c,d,f   Seror, Raphaèle ^a,b,e   Mariette, Xavier ^a,b,e  

^a INSERM U1184   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CHRU Brest   (France)

^d Universite de Brest   (France)

^e BICÊTRE HOSPITAL   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

Author keywords

B cell; Biologics; Clinical trials; Outcome measure; Primary Sj gren syndrome

Indexed keywords

ABATACEPT; BAMINERCEPT; BELIMUMAB; EPRATUZUMAB; INFLIXIMAB; INTERFERON; LYMPHOTOXIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; HELPER CELL; HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SJOEGREN SYNDROME; BIOLOGICAL THERAPY; IMMUNOLOGY; PROCEDURES;

BIOLOGICAL THERAPY; HUMANS; SJOGREN'S SYNDROME;

EID: 84964345300     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.02.009     Document Type: Review

References (79)

1. M. Ramos-Casals, R. Solans, J. Rosas, and et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients Medicine (Baltimore) 87 4 2008 Jul 210 219
2. M. Ramos-Casals, A.G. Tzioufas, J.H. Stone, and et al. Treatment of primary Sjogren syndrome: a systematic review Jama 304 4 2010 Jul 28 452 460
3. S. Dass, S.J. Bowman, E.M. Vital, and et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study Annals of the Rheumatic Diseases 67 11 2008 Nov 1541 1544
4. V. Devauchelle-Pensec, X. Mariette, S. Jousse-Joulin, and et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial Annals of Internal Medicine 160 4 2014 Feb 18 233 242
5. X. Mariette, P. Ravaud, S. Steinfeld, and et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS) Arthritis & Rheumatology 50 4 2004 Apr 1270 1276
6. V. Sankar, M.T. Brennan, M.R. Kok, and et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial Arthritis & Rheumatology 50 7 2004 Jul 2240 2245
7. R. Seror, P. Ravaud, S.J. Bowman, and et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome Annals of the Rheumatic Diseases 69 6 2010 Jun 1103 1109
8. R. Seror, X. Mariette, S. Bowman, and et al. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European league against rheumatism Sjogren's syndrome disease activity index Arthritis Care & Research (Hoboken) 62 4 2010 Apr 551 558
9. R. Seror, E. Theander, J.G. Brun, and et al. Validation of EULAR primary Sjögren's syndrome disease activity and patient indexes Arthritis and Rheumatism 64 10 2013 S1078
10. J.E. Gottenberg, R. Seror, C. Miceli-Richard, and et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort PLoS One 8 5 2013 e59868
11. M. Pertovaara, and M. Korpela Serum beta2 microglobulin correlates with the new ESSDAI in patients with Sjogren's syndrome Annals of the Rheumatic Diseases 70 12 2011 Dec 2236 2237
12. L. Quartuccio, S. Salvin, M. Fabris, and et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands Rheumatology (Oxford, England) 52 2 2013 Feb 276 281
13. G.J. Tobon, A. Saraux, J.E. Gottenberg, and et al. The FMS-like tyrosine kinase 3-ligand may be biological marker of lymphoma in primary Sjogren's syndrome Arthritis and Rheumatism 62 11 2013 Aug 3447 3456
14. G. Nocturne, A. Virone, W.F. Ng, and et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's Syndrome Arthritis & Rheumatology 2015 Nov 25 10.1002/art.39518 [Epub ahead of print]
15. R. Seror, H. Bootsma, A. Saraux, and et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) Annals of the rheumatic diseases 75 2 2016 Feb 382 389
16. S.J. Bowman, D.A. Booth, R.G. Platts, and et al. Validation of the sicca symptoms inventory for clinical studies of Sjogren's syndrome The Journal of Rheumatology 30 6 2003 Jun 1259 1266
17. S.J. Bowman, D.A. Booth, and R.G. Platts Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool Rheumatology (Oxford, England) 43 6 2004 Jun 758 764
18. D. Cornec, V. Devauchelle-Pensec, X. Mariette, and et al. Development of the Sjogren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy Rheumatology (Oxford, England) 54 9 2015 Sep 1699 1708
19. S. Jousse-Joulin, V. Devauchelle-Pensec, D. Cornec, and et al. Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjogren's syndrome Arthritis & Rheumatology 67 6 2015 Jun 1623 1628
20. C. Oni, S. Mitchell, K. James, and et al. Eligibility for clinical trials in primary Sjogren's syndrome: lessons from the Uk Primary Sjogren's Syndrome Registry Rheumatology (Oxford) 55 3 2016 Mar 544 552
21. V. Devauchelle-Pensec, J.E. Gottenberg, S. Jousse-Joulin, and et al. Which and how Many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sjogren's syndrome? PLoS One 10 9 2015 e0133907
22. D. Cornec, V. Devauchelle-Pensec, G.J. Tobon, and et al. B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment Journal of Autoimmunity 39 3 2012 Sep 161 167
23. G. Nocturne, and X. Mariette Sjogren Syndrome-associated lymphomas: an update on pathogenesis and management British Journal of Haematology 168 3 2015 Feb 317 327
24. M. Thien, T.G. Phan, S. Gardam, and et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches Immunity 20 6 2004 Jun 785 798
25. X. Mariette, S. Roux, J. Zhang, and et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome Annals of the Rheumatic Diseases 62 2 2003 Feb 168 171
26. C. Daridon, V. Devauchelle, P. Hutin, and et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome Arthritis & Rheumatology 56 4 2007 Apr 1134 1144
27. F. Lavie, C. Miceli-Richard, M. Ittah, and et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome Scandinavian Journal of Immunology 67 2 2008 Feb 185 192
28. S.A. Chambers, and D. Isenberg Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases Lupus 14 3 2005 210 214
29. J.E. Gottenberg, L. Guillevin, O. Lambotte, and et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Annals of the Rheumatic Diseases 64 6 2005 Jun 913 920
30. J. Pijpe, G.W. van Imhoff, F.K. Spijkervet, and et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study Arthritis and Rheumatism 52 9 2005 Sep 2740 2750
31. V. Devauchelle-Pensec, Y. Pennec, J. Morvan, and et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20) Arthritis and Rheumatism 57 2 2007 Mar 15 310 317
32. E.W. St Clair, M.C. Levesque, E.T. Prak, and et al. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis Arthritis and Rheumatism 65 4 2013 Apr 1097 1106
33. V. Devauchelle-Pensec, J. Morvan, A.C. Rat, and et al. Effects of rituximab therapy on quality of life in patients with primary Sjogren's syndrome Clinical and Experimental Rheumatology 29 1 2011 Jan-Feb 6 12
34. J.M. Meijer, J. Pijpe, A. Vissink, and et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment Annals of the Rheumatic Diseases 68 2 2009 Feb 284 285
35. F. Carubbi, P. Cipriani, A. Marrelli, and et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study Arthritis Research & Therapy 15 5 2013 R172
36. R. Seror, C. Sordet, L. Guillevin, and et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome Annals of the Rheumatic Diseases 66 3 2007 Mar 351 357
37. J.E. Gottenberg, G. Cinquetti, C. Larroche, and et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry Annals of the Rheumatic Diseases 72 6 2013 Jun 1026 1031
38. A. Mekinian, P. Ravaud, P.Y. Hatron, and et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry Annals of the Rheumatic Diseases 71 1 2012 Jan 84 87
39. J.M. Meijer, P.M. Meiners, A. Vissink, and et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial Arthritis & Rheumatology 62 4 2010 Apr 960 968
40. S. Brown, N. Navarro Coy, C. Pitzalis, and et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogren's Syndrome BMC Musculoskeletal Disorder 15 2014 21
41. ACR S. Bowman, C. Everett, M. Bombardieri, and et al. Preliminary results of a double-blind randomised trial of rituximab Anti-B-Cell therapy in patients with primary Sjogrens syndrome 2015 [San Francisco]
42. N. Sieger, S.J. Fleischer, H.E. Mei, and et al. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation Arthritis & Rheumatology 65 3 2013 Mar 770 779
43. D.J. Wallace, K. Kalunian, M.A. Petri, and et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Annals of the Rheumatic Diseases 73 1 2014 Jan 183 190
44. M.E.B. Clowse, D.J. Wallace, R. Furie, and et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: results from two phase 3 randomized, Placebo-Controlled Trials [abstract] ACR Meeting; San Francisco Arthritis & Rheumatology 67 10 2015
45. S.D. Steinfeld, L. Tant, G.R. Burmester, and et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study Arthritis Research & Therapy 8 4 2006 R129
46. L. Chiche, N. Jourde, G. Thomas, and et al. New treatment options for lupus - a focus on belimumab Journal of Therapeutics and Clinical Risk Management 8 2012 33 43
47. S.V. Navarra, R.M. Guzman, A.E. Gallacher, and et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 9767 2011 Feb 26 721 731
48. X. Mariette, R. Seror, L. Quartuccio, and et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study Annals of the Rheumatic Diseases 74 3 2015 Mar 526 531
49. A.K. Palucka, J.P. Blanck, L. Bennett, and et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases Proceedings of the National Academy of Sciences of the United States of America 102(9) 2005 Mar 1 3372 3377
50. G. Nocturne, and X. Mariette Advances in understanding the pathogenesis of primary Sjogren's syndrome Nature Reviews Rheumatology 9 9 2013 Sep 544 556
51. K.B. Norheim, E. Harboe, L.G. Goransson, and et al. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-a double blind, randomised clinical trial PLoS One 7 1 2012 e30123
52. R.P. Pollard, W.H. Abdulahad, A. Vissink, and et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial Annals of the Rheumatic Diseases 72 1 2013 Jan 146 148
53. F. Lavie, C. Miceli-Richard, M. Ittah, and et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production Annals of the Rheumatic Diseases 66 5 2007 May 700 703
54. D. Cornec, S. Costa, V. Devauchelle-Pensec, and et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome Journal of Autoimmunity 67 2016 Feb 102 110
55. A. Snir, A. Kessel, T. Haj, and et al. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy Clinical and Experimental Rheumatology 29 4 2011 Jul-Aug 697 700
56. A. Halse, P. Tengner, M. Wahren-Herlenius, and et al. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren's syndrome Scandinavian Journal of Immunology 49 5 1999 May 533 538
57. M. Tishler, I. Yaron, O. Geyer, and et al. Elevated tear interleukin-6 levels in patients with Sjogren syndrome Ophthalmology 105 12 1998 Dec 2327 2329
58. M. Tishler, I. Yaron, I. Shirazi, and et al. Increased salivary interleukin-6 levels in patients with primary Sjogren's syndrome Rheumatology International 18 4 1999 125 127
59. + T cells in women with primary Sjogren's syndrome Scandinavian Journal of Immunology 79 1 2014 Jan 37 42
60. M.L. Wang, S. Rule, P. Martin, and et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma New England Journal of Medicine 369 6 2013 Aug 8 507 516
61. W.H. Wilson, R.M. Young, R. Schmitz, and et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Nature Medicine 21 8 2015 Aug 922 926
62. S. Ponader, and J.A. Burger Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies Journal of Clinical Oncology 32 17 2014 Jun 10 1830 1839
63. L.P. Kil, M.J. de Bruijn, M. van Nimwegen, and et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice Blood 119 16 2012 Apr 19 3744 3756
64. F. Ramadani, D.J. Bolland, F. Garcon, and et al. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development Science Signalling 3 134 2010 ra60
65. R.R. Furman, J.P. Sharman, S.E. Coutre, and et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia New England Journal of Medicine 370 11 2014 Mar 13 997 1007
66. A.K. Gopal, B.S. Kahl, S. de Vos, and et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma New England Journal of Medicine 370 11 2014 Mar 13 1008 1018
67. S. Salomonsson, M.V. Jonsson, K. Skarstein, and et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome Arthritis & Rheumatology 48 11 2003 Nov 3187 3201
68. N. Amft, S.J. Curnow, D. Scheel-Toellner, and et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome Arthritis & Rheumatology 44 11 2001 Nov 2633 2641
69. M. Bombardieri, F. Barone, D. Lucchesi, and et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice The Journal of Immunology 189 7 2012 Oct 1 3767 3776
70. A.K. Halse, M.C. Marthinussen, M. Wahren-Herlenius, and et al. Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjogren's syndrome Scandinavian Journal of Rheumatology 29 1 2000 13 19
71. E. Theander, L. Vasaitis, E. Baecklund, and et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome Annals of the Rheumatic Diseases 70 8 2011 Aug 1363 1368
72. C. Pitzalis, G.W. Jones, M. Bombardieri, and et al. Ectopic lymphoid-like structures in infection, cancer and autoimmunity Nature Reviews Immunology 14 7 2014 Jul 447 462
73. E.W. St Clair, A.N. Baer, G. Noaiseh, and et al. The clinical efficacy and safety of baminercept, a lymphotoxin-beta receptor fusion protein, in primary Sjögren's syndrome: results from a randomized, double-blind, placebo-controlled phase II trial ACR Meeting; San Francisco 2015
74. S. Crotty Follicular helper CD4 T cells (TFH) Annual Review of Immunology 29 2011 621 663
75. Y.Z. Gong, J. Nititham, K. Taylor, and et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren's syndrome Journal of Autoimmunity 2014 Jan 9 [Epub ahead of print]
76. S. Adler, M. Korner, F. Forger, and et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study Arthritis Care & Research (Hoboken) 65 11 2013 Nov 1862 1868
77. P.M. Meiners, A. Vissink, F.G. Kroese, and et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study) Annals of the Rheumatic Diseases 73 7 2014 Jul 1393 1396
78. J.C. Hall, A.N. Baer, A.A. Shah, and et al. Molecular subsetting of interferon pathways in Sjogren's syndrome Annals of the Rheumatic Diseases 67 9 2015 Sep 2437 2446
79. J.E. Gottenberg, P. Ravaud, X. Puechal, and et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial Jama 312 3 2014 Jul 16 249 258